Urine and Plasma Markers of Platelet Activation and Respiratory Symptoms in COPD

Abstract

Introduction: Antiplatelet therapy has been associated with fewer exacerbations and reduced respiratory symptoms in chronic obstructive pulmonary disease (COPD). Whether platelet activation is associated with respiratory symptoms in COPD is unknown.

Methods: Former smokers with spirometry-confirmed COPD had urine 11-dehydro-thromboxane B2 (11dTxB2), plasma soluble CD40L (sCD40L), and soluble P-selectin (sP-selectin) repeatedly measured during a 6- to 9-month study period. Multivariate mixed-effects models adjusted for demographics, clinical characteristics, and medication use evaluated the association of each biomarker with respiratory symptoms, health status, and quality of life.

Results: Among 169 participants (average age 66.5±8.2 years, 51.5% female, 47.5±31 pack years, forced expiratory volume in 1 second percent predicted 53.8±17.1), a 100% increase in 11dTxB2 was associated with worse respiratory symptoms reflected by higher scores on the COPD Assessment Test (β 0.77, 95% confidence interval [CI]: 0.11–1.4) and Ease of Cough and Sputum Clearance Questionnaire β 0.77, 95%CI: 0.38–1.2, worse health status (Clinical COPD Questionnaire β 0.13, 95%CI: 0.03-0.23) and worse quality of life (St George’s Respiratory Questionnaire β 1.9, 95%CI: 0.39-3.4). No statistically significant associations were observed for sCD40L or sP-selectin. There was no consistent statistically significant effect modification of the relationship between urine 11dTxB2 and respiratory outcomes by history of cardiovascular disease, subclinical coronary artery disease, antiplatelet therapy, or COPD severity.

Conclusions: In stable moderate-severe COPD, elevated urinary11dTxB2, a metabolite of the platelet activation product thromboxane A2, was associated with worse respiratory symptoms, health status, and quality of life.

Introduction

Extrapulmonary manifestations of chronic obstructive pulmonary disease (COPD) include heightened systemic inflammation, defective immune response, and increased risk for cardiovascular disease (CVD) and thrombosis.^1-5 In addition to their well-known roles in CVD and thrombosis, activated platelets are critical for trafficking immune cells and release cytokines and chemokines that perpetuate systemic inflammation or act directly on the respiratory system.^6-9 Several studies have reported on abnormal platelet indices in COPD, such as elevated platelet count and mean platelet volume, as potential surrogates of platelet activation and have shown adverse outcomes in both stable and exacerbated COPD.^10-14 Limited studies have demonstrated increased platelet activation in individuals with stable COPD compared with healthy controls with even further elevation during acute exacerbations.^15-17 Furthermore, persistently elevated platelet reactivity despite anti-platelet therapy after percutaneous coronary intervention was significantly more common among individuals with COPD compared with matched controls.¹⁸ Whether higher levels of platelet activation among individuals with COPD impacts respiratory morbidity and outcomes remains unknown.

Activated platelets release thromboxane A2 (TxA2), which is a prostanoid produced by the enzymatic action of cyclooxygenase-1 (COX-1) on arachidonic acid. TxA2 is itself a strong platelet activator, causing feedback activation and recruitment of additional platelets to vascular sites.¹⁹ In the lung, TxA2 acts on airway smooth muscles, causing bronchoconstriction, airway hyper-responsiveness, and remodeling.^20,21 Direct measurement of TxA2 is difficult and inaccurate given its extremely short half-life (≤30 seconds), however, a stable urinary metabolite, 11-dehydro-thromboxane-B2 (11dTxB2), offers an opportunity to indirectly measure platelet activation that occurs in vivo. In observational studies of individuals with COPD, aspirin, which acetylates and permanently inactivates COX-1 in platelets, has been associated with lower all-cause mortality, lower incidence rate of acute exacerbations of COPD (AECOPDs), less severe AECOPDs, better quality of life, less dyspnea, and slower progression of subclinical emphysema.^10,22-28

Activated platelets also release additional molecules that are stored in α and dense granules. Measuring these molecules is another method to determine the degree of in vivo platelet activation.²⁹ CD40 ligand (CD40L) and P-selectin are a granule constituents that become expressed on the platelet surface after activation, and both can be secreted as soluble biologically active molecules that can be measured in plasma (sCD40L and sP-selectin). When expressed on the surface of activated platelets, CD40L activates the endothelium to secrete chemokines and express adhesion molecules while P-selectin recruits leukocytes via its counter-receptor, P-selectin glycoprotein ligand-1 (PSGL-1).^6,7,30,31

The aim of this study was to evaluate the association of platelet activation markers — urine 11dTxB2, plasma sCD40L, and plasma sP-selectin— with respiratory symptoms in a cohort of individuals with stable COPD. The a priori hypothesis was that elevated levels of platelet activation markers would be associated with increased respiratory symptoms, worse health status, and worse quality of life.

Methods

Participants

This is a secondary analysis of data from the Clinical Trial of Air Cleaners to Improve Indoor Air Quality and COPD Health (CLEAN AIR) study (ClinicalTrials.gov #NCT02236858) and Comparing Urban and Rural Effects of Poverty on COPD (CURE COPD) study. Both studies enrolled former smokers (≥10 pack-year history) with stable moderate-severe COPD (forced expiratory volume in 1 second [FEV₁] to forced vital capacity [FVC] ≤70% and FEV₁<80% predicted). CLEAN AIR was a double-blind clinical trial that randomized participants to active air cleaners with HEPA and carbon filters or a sham and is described in detail elsewhere.³² CURE COPD was an observational study evaluating the interactive effects of indoor air pollution and diet. For 39 participants who enrolled in both studies, only data from CLEAN AIR was included in the analysis. CLEAN AIR participants had 5 visits over a 9-month period (3 months prior to randomization, at randomization, then at 1 week, 3 months, and 6 months post-randomization) and CURE COPD participants had 3 visits over a 6-month period (baseline, 3 months, and 6 months) (Figure 1). Each study was approved by the Johns Hopkins University Institutional Review Board and all participants provided written informed consent.

Measurements

Urine samples were collected at each study visit and ethylenediaminetetraacetic acid (EDTA) plasma was additionally collected in CLEAN AIR. A complete blood count was analyzed in the clinical laboratory immediately following sample collection. Urine and plasma samples were processed within 2 hours of collection, stored at -80⁰C, and analyzed in a single batch at the Johns Hopkins Institute for Clinical and Translational Research (JH ICTR) Core Laboratory. The primary biomarker of interest was urine 11dTxB2 which was measured using a commercially available enzyme-linked immunoassay (ELISA) kit (Enzo Life Sciences, Lyon, France;pg/mL). The secondary biomarkers of interest were likewise measured by ELISA: plasma sP-selectin (R&D Systems, Minneapolis, Minnesota;ng/mL) and plasma sCD40L (R&D Systems, Minneapolis, Minnesota;pg/mL). Urine 11dTxB2 was adjusted by dividing the measured value by urine creatinine which was also measured by ELISA (Quidel Corporation, San Diego, CA;mg/mL) at the JH ICTR Core Laboratory.

Medical history was obtained at baseline using structured questionnaires. Although antiplatelet therapy use was not explicitly solicited, participants were asked to bring all medications they used in the last 3 months to each study visit. Research staff transcribed a list of medications at each study visit which were parsed for generic and trade names of antiplatelet therapies (aspirin, clopidogrel, prasugrel, ticagrelor). A participant was determined to be on a specific antiplatelet therapy during the entire study period if the medication appeared on their medication list at least once during the study. Spirometry was performed according to the American Thoracic Society protocol (Koko spirometer; nSpire) at each visit and post-bronchodilator percent predicted values calculated.³³ Non-contrast non-electrocardiography-gated computed tomography (CT) scans of the chest were performed once during the study period, reconstructed at contiguous 0.75 mm and 3 mm thickness slices. Coronary artery calcium (CAC) score (Agatston score) was quantified by a single fellowship-trained cardiothoracic radiologist (C.T.L.) on inspiratory CT scans using the calcium scoring tool on either Carestream Vue PACS (version 12.2.2.0105) or Syngo.Via (version VB40B). Non-gated CT scans have demonstrated good agreement and reliability for quantification of CAC relative to electrocardiography-gated CT scans, although they tend to systematically underestimate CAC burden.^34,35

Outcomes

Clinical outcomes ascertained at each visit included respiratory symptoms (COPD Assessment Test [CAT],³⁶ modified Medical Research Council questionnaire [mMRC],³⁷ Ease of Cough and Sputum Clearance questionnaire [ECSC],³⁸ and Breathlessness, Cough, and Sputum Scale [BCSS]),³⁹ and health status (Clinical COPD Questionnaire [CCQ]).⁴⁰ Quality of life (St George’s Respiratory Questionnaire [SGRQ])⁴¹ was ascertained at all visits except the 1-week follow-up in CLEAN AIR. The total score of all outcomes were evaluated as continuous variables and the minimal clinically important difference has been established⁴² for most: CAT (2 units),⁴³ SGRQ (4 units),⁴⁴ CCQ (0.3–0.5 points),⁴⁵ BCSS (small improvement=0.3 units, moderate improvement=0.6 units, substantial improvement >1 unit).³⁹

Statistical Analysis

Baseline characteristics were described and compared using chi-squared, Fisher’s exact test, or t-test between participants in the 2 studies. A comparison of the baseline distribution of each biomarker was performed using the Wilcoxon rank sum test for aspirin use, history of CVD, and evidence of sub-clinical coronary artery disease (CAD) using presence of CAC on CT scan (Agatston score=0 versus >0).⁴⁶ To estimate the association of each biomarker with the outcomes of interest, a generalized linear mixed model with random intercept for participants was used. Biomarkers were modeled continuously and log-transformed, and the linearity assumption was tested using restricted cubic splines. In the case where non-linearity was suggested, the biomarker was modeled categorically as quartiles (i.e., sP-selectin). Multivariate models were adjusted for factors that may impact respiratory outcomes or degree of systemic platelet activation, including study (CURE versus CLEAN AIR intervention versus CLEAN AIR control), time (in months), and its interaction with study group, age, gender, race (Black versus White or other), educational attainment (≤high school versus >high school), body mass index, lung function (percent predicted FEV₁), pack-year smoking history, CVD history, diabetes history, and use of antiplatelet therapy (aspirin or clopidogrel). CVD history was defined as self-reported baseline history of congestive heart failure, stroke, heart attack, percutaneous coronary angiography, or circulatory disease. Disaggregation of within- and between-person effects was explored.⁴⁷ Sensitivity analyses were conducted including adding platelet count and MPV as covariates to biomarker models and limiting the analysis of urine 11dTxB2 to participants and study visits with plasma samples available to investigate whether any discrepancy in findings between urine and plasma biomarkers are attributable to selection bias. Effect modification by history of CVD, presence of CAC, antiplatelet therapy use, study enrollment, and COPD disease severity (categorized as mild/moderate [FEV₁ ≥50%] and severe/very severe [FEV₁ <50%]) were explored for the relationship between urine 11dTxB2 and outcomes using an interaction term for urine 11dTxB2, and the effect modifier of interest and subgroup analysis results are presented. Additionally, effect modification by history of CVD and presence of CAC was explored in a subset of participants not on antiplatelet therapy. Analysis of effect modification for sCD40L and sP-selectin is not presented due to small sample size of the subgroups. All analyses were conducted using SAS 9.4 (Carey, North Carolina) and all statistical comparisons including interactions were considered significant at p<0.05.

Results

There were 192 unique participants after excluding CURE COPD data for dual enrolled participants. Individuals were additionally excluded for missing biomarker data (19, 9.9%) or baseline spirometry that did not meet acceptability and repeatability criteria³³ (4, 2.1%) resulting in a final sample of 169 participants, of whom 113 (66.9%) were enrolled in CLEAN AIR (57 intervention, 56 control) and 56 (33.1%) were enrolled in CURE COPD. Baseline characteristics are presented in Table 1. Compared to participants in CLEAN AIR, CURE COPD participants were older, more likely to be Black and reported fewer pack years smoked (Supplemental Table 1 in the online supplement). In sum, 16.3% of visits had missing urine samples and 11.9% had missing plasma samples (collected in the CLEAN AIR study only), with a greater proportion at 3- and 6-month follow-up, resulting in a total of 630 urine and 505 plasma samples (Supplemental Table 2 in the online supplement). The distribution of 11dTxB2, sCD40L, and sP-selectin at each visit is also presented in Supplemental Table 2 in the online supplement. Among participants who had more than 1 measurement, the median within-person difference (maximum-minimum/minimum) was 95% for 11dTxB2 (N=154) and 132% for sCD40L (N=112) and thus, results are reported per 100% change (doubling) of the biomarker. Baseline 11dTxB2 was higher among CLEAN AIR participants compared with CURE COPD participants (5500±2748 versus 3503±1991 pg/mg Cr; p<0.0001). Half of the participants (N=87) were aspirin users of whom 12 (13.8%) were concomitantly using clopidogrel while none reported using prasugrel, ticagrelor, or clopidogrel monotherapy. Individuals who reported antiplatelet therapy use had significantly lower baseline 11dTxB2 compared with antiplatelet therapy non-users with no difference in sCD40L or sP-selectin between the 2 groups (Supplemental Table 2 in the online supplement). SGRQ, which was not ascertained at the 1-week follow-up, was missing in 7.5% of visits (available N=573), BCSS was missing in 12% (available N=644), while the remainder of the questionnaires had approximately 7% missing (available N=679–685).

In multivariate analysis (Figure 2), a 100% increase in 11dTxB2 was associated with worse symptoms (CAT score mean difference [β] 0.77, 95% confidence interval [CI]: 0.11, 1.4; ECSC β 0.77, 95%CI: 0.38, 1.2), worse health status (CCQ score β 0.13, 95%CI: 0.03, 0.23), and worse quality of life (SGRQ score β 1.9, 95%CI: 0.39, 3.4). The association of 11dTxB2 with mMRC (β 0.1, 95%CI: -0.007, 0.20) and BCSS (β 0.31, 95%CI -0.001, 0.62) did not reach statistical significance. The observed associations appear to be related to within-person effect (Supplemental Table 3 in the online supplement). No statistically significant associations were observed for sCD40L (Supplemental Figure 1 in the online supplement) or sP-selectin (Supplemental Figure 2 in the online supplement). sP-selectin was modeled categorically as quartiles due to the evidence of non-linear relationships with a few of the outcomes. Additional adjustment of the biomarker models with platelet count and mean platelet volume did not substantially impact the findings (results not shown).

Antiplatelet therapy use was higher among individuals who reported a history of CVD (63.3%) compared with those without a history of CVD (41.1%, p=0.004) and higher prevalence among those with CAC compared to those without CAC (55.1% versus 41.4%; p=0.2). There was no significant difference in the distribution of any of the biomarkers between participants with history of CVD compared to those without CVD or those with CAC compared to those without CAC although median urine 11dTxB2 was higher among participants without CVD history or CAC while sCD40L and sP-selectin were higher among participants with CVD history or CAC (Supplemental Table 2 in the online supplement). There was no consistently, statistically significant effect modification of the association between urine 11dTxB2 and respiratory outcomes by history of CVD, presence of CAC, antiplatelet therapy use, study enrollment, or COPD severity and subgroup analyses did not reveal any consistent trends (Figure 3). Among aspirin non-users, median levels of all biomarkers were higher among participants without CVD and participants with CAC>0 (Supplemental Table 4 in the online supplement). When limited to aspirin non-users, results were consistent with stronger association of urine 11dTxB2 with health status (CCQ; p_interaction=0.03) and quality of life (SGRQ; p_interaction=0.06) among individuals with CAC>0 (Supplemental Figure 3 in the online supplement). A sensitivity analysis of urine 11dTxB2 limited to participants and visits where plasma samples were available demonstrated consistent results for all respiratory outcomes, though estimates were attenuated and no longer statistically significant for CCQ and SGRQ (Supplemental Figure 4 in the online supplement).

Discussion

Among individuals with stable moderate-severe COPD, elevated urine 11dTxB2, a biomarker of platelet activation, was consistently associated with significantly worse respiratory symptoms, health status, and quality of life independent of comorbid cardiovascular disease. This was largely driven by within-person differences in biomarker and respiratory symptoms. There were no associations between the plasma biomarkers (sCD40L and sP-selectin) and respiratory outcomes. To our knowledge this is the first study investigating the association of systemic biomarkers of platelet activation and respiratory symptoms in COPD and suggests a role of platelet activation through the TxA2 pathway in respiratory morbidity among individuals with COPD.

Of the 3 platelet biomarkers investigated, 11dTxB2 most closely reflects systemic platelet activation. Urine 11dTxB2 is one of several metabolites of TxA2 which is generated and released from the action of COX on arachidonic acid when platelets are activated. Urine 11dTxB2 is commonly used as a non-invasive measure of in vivo platelet activation,^48,49 although, its concentration may also reflect vascular, renal, and immune cell production, or differences in excretion.⁵⁰ In contrast, P-selectin and CD40L are stored in alpha granules that are transported to the surface upon platelet activation. A portion of the stored P-selectin and CD40L is retained on the platelet surface to facilitate interactions with leukocytes and endothelium while the remainder is secreted. There is evidence that the majority of circulating sP-selectin is of platelet origin and that sCD40L is correlated with platelet-monocyte aggregates, a sensitive marker of platelet activation.^51-53 However, sP-selectin may originate from endothelial cells or be resorbed by platelets for recycling while sCD40L may have been cleaved from the surface of immune cells.^54,55 The non-specific origin and complex mechanisms of sP-selectin and sCD40L complicates interpretation of those results. The discrepant results between urine 11dTxB2 and the plasma platelet activation markers may alternatively be attributable to in vitro platelet activation during acquisition, processing, and storage of plasma samples. Since the parent study that contributed plasma samples was not designed for the purpose of evaluating markers of platelet activation,³² precautions to minimize in vitro platelet activation were not protocolized. Such precautions include drawing the sample from the antecubital fossa using a large needle, removing the tourniquet prior to sample collection, discarding several mL of blood before acquisition of the plasma sample, and minimizing the time between collection and processing of the sample.⁵⁶ Conversely, use of EDTA as the plasma anticoagulant would have inhibited sCD40L release that may have become activated after collection or during sample storage.⁵⁷

This study did not find any significant effect modification of the association between 11dTxB2 and respiratory outcomes by self-reported history of CVD or subclinical CAD as determined by presence of coronary artery calcification. Thus, the association between activated platelets and worse respiratory symptoms was present among individuals with and without underlying CVD or CAD. Respiratory outcomes in COPD have been difficult to distinguish from respiratory manifestations of cardiac symptoms which may complicate interpretation of platelet activation markers that have been associated with cardiovascular disease. Presence of an association between 11dTxB2 and respiratory outcomes regardless of clinical or subclinical CVD reduces the possibility that patient-reported respiratory symptoms are manifestations of CVD, though further study is warranted.

The findings of this study build upon a previous study showing reduced respiratory symptoms, better quality of life, and fewer exacerbations among individuals with COPD reporting daily aspirin use compared to aspirin non-users.²⁸ Other studies have reported that aspirin use was associated with reduced all-cause mortality in stable COPD and following COPD exacerbation,^10,25 less severe COPD exacerbations,²⁴ and slower progression of subclinical emphysema.²⁷ Aspirin is an antiplatelet agent that specifically antagonizes TxA2 synthesis, the pathway found to be associated with worse respiratory morbidity in this study. TxA2 or its synthetic analog, have been shown to cause bronchoconstriction in both humans and animal models, potentially mediated by airway muscarinic receptors, a target of first line COPD therapy.^20,58 In clinical trials of asthma patients, seratrodast, a TxA2 receptor antagonist, decreased airway responsiveness to methacholine, improved symptoms, and increased peak expiratory flow.^59,60 It is currently recommended as add-on therapy in the treatment of asthma in Japan.⁶¹ A crossover trial of 15 individuals with emphysema due to alpha-1 antitrypsin deficiency did not show any significant difference in microvascular blood flow with low-dose aspirin compared to placebo.⁶² Future clinical trials evaluating the impact of aspirin or thromboxane A2 receptor antagonists on platelet activation suppression and respiratory symptoms in more heterogenous COPD samples are warranted.

This study has limitations. The relatively small sample size reduces the power to detect between-person effects, which may have conservatively biased estimates, in this study that drew its power from repeated measurements and identification of within-person effects. Associations between 11dTxB2 and clinical outcomes did not reach the minimal clinically important differences. Furthermore, there may be residual confounding as a consequence of this study including secondary analysis of clinical trial data, although, the study intervention arm was included as a covariate. Comorbidities were self-reported and antiplatelet therapy including dose and adherence were not specifically ascertained which may result in misclassification due to recall bias. Additionally, there were few individuals on P2Y12-antagonist medications and none using it as monotherapy which precluded investigation of that therapeutic class of antiplatelet medications independently of aspirin. Finally, although aspirin use has been associated with reduced incidence of COPD exacerbations,²⁸ due to the short follow-up period and paucity of events, this study was unable to assess the association between platelet activation biomarkers and COPD exacerbations.

In conclusion, elevated urinary 11dTxB2, a marker of COX-mediated platelet activation, was associated with worse respiratory symptoms and quality of life independent of reported cardiovascular disease or coronary artery calcification; however, this was not reflected by sP-selectin and sCD40L. Future studies employing more specific measures of platelet activation or evaluating the efficacy of aspirin or a targeted thromboxane inhibitor in COPD are warranted.

Abbreviations

Abbreviations: 11dTxB2=11-dehydro-thromboxane B2; AECOPD= acute exacerbation of COPD; BCSS=Breathlessness, Cough, and Sputum Scale; CAC=coronary artery calcium; CAD=coronary artery disease; CAT=COPD Assessment Test; CCQ=Clinical COPD Questionnaire; CD40L=CD40 Ligend; CI=confidence interval; COPD=chronic obstructive pulmonary disease; COX-1=cyclooxygerase-1; CT=computed tomography; CVC=cardiovascular disease; ECSC=Ease of Cough and Sputum Clearance Questionnaire; EDTA=ethylene diaminetetraacetic acid; ELISA=enzyme-linked immunoassay; FEV₁=forced expiratory volume in 1 second; FVC=forced vital capacity; JH ICTR=Johns Hopkins Institute for Clinical and Translational Research, mMRC=modified Medical Research Council; PSGL-1=P-selection glycoprotein ligand-1; SCD40L=soluble CD40L; SGRQ=St George’s Respiratory Questionnaire; sP-selectin=soluble P-selectin; TxA2=thromboxane A-2

Funding Statement

The Clinical Trial of Air Cleaners to Improve Indoor air Quality and COPD Health (CLEAN AIR) was supported by the National Institute of Environmental Health Sciences (NIEHS) R01ES022607. CLEAN AIR HEART was supported by NIEHS R21ES025840. The Comparing Urban and Rural Effects of Poverty on COPD (CURE COPD) study was supported by National Institute on Minority Health Disparities P50MD010431. AF was supported by the National Heart Lung and Blood Institute (NHLBI) T32HL007534, NIEHS F32ES028576, and NHLBI K23HL151758. NP was supported by K23HL123594. Trial Registration: ClinicalTrials.gov Identifier #NCT02236858